Formulary guidance and transparency from P&T to point of care

Trends That Matter for G-CSF Treatments

Posted by Matt Breese on Nov 30, 2017

Find me on:



In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is granulocyte-colony stimulating factor (G-CSF) treatments. 

According to MMIT's recent payer coverage analysis for G-CSF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape. Here’s a look at more recent trends.

  • Prescriber Attitude Shifts to GCSFs: An international study demonstrates the increasing likelihood of prescribers to select lower cost GCSFs when appropriate clinical and regulatory data is present, which can be connected to specific patient profiles. 
  • Biosimilar Debut and Utilization Correlation: Recent research reveals that the utilization of granulocyte-colony stimulating factors (G-CSF) increases following the launch of biosimilar versions across the globe. While most research derives from Europe, experts expect the same trend in the United States.
  • Biosimilar Competition on the Horizon: Due to the rapidly growing revenue of the G-CSF space, many emerging biologic pharma manufacturers invest development dollars into the space. While Zarxio represents the first biosimilar in the space, the market can expect additional competition in the near future

To learn more about this topic, download MMIT's Reality Check by clicking on the button below: 

View Reality Check 

Topics: Industry Trends, Market Access, Payer